Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer

Yakabe, Tomomi; Noshirο, Hirokazu; Ikeda, Osamu; Miyoshi, Anderson; Kitajima, Yoshihiko; Satoh, Seiji

doi:10.1007/s00432-011-1025-x

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, little change in IgE level was found in the nanoparticle groups, suggesting that our nanoparticle formulations could reduce the risk of hypersensitivity reactions. The blood of mice was also collected to analyze the blood cell counts, which are often used as the indicator of hematotoxicity (Figure B) . The total WBC/PLT counts of mice treated with Taxol showed an obvious decrease over the normal group ( P < 0.05).…”

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Insoluble Cargo (Paclitaxel) by PEGylated Chitosan Nanoparticles Grafted with Arg-Gly-Asp (RGD)

et al. 2012

Mol. Pharmaceutics

View full text Add to dashboard Cite

Poor delivery of insoluble anticancer drugs has so far precluded their clinical application. In this study, we developed a tumor-targeting delivery system for insoluble drug (paclitaxel, PTX) by PEGylated O-carboxymethyl-chitosan (CMC) nanoparticles grafted with cyclic Arg-Gly-Asp (RGD) peptide. To improve the loading efficiency (LE), we combined O/W/O double emulsion method with temperature-programmed solidification technique and controlled PTX within the matrix network as in situ nanocrystallite form. Furthermore, these CMC nanoparticles were PEGylated, which could reduce recognition by the reticuloendothelial system (RES) and prolong the circulation time in blood. In addition, further graft of cyclic RGD peptide at the terminal of PEG chain endowed these nanoparticles with higher affinity to in vitro Lewis lung carcinoma (LLC) cells and in vivo tumor tissue. These outstanding properties enabled as-designed nanodevice to exhibit a greater tumor growth inhibition effect and much lower side effects over the commercial formulation Taxol.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Insoluble Cargo (Paclitaxel) by PEGylated Chitosan Nanoparticles Grafted with Arg-Gly-Asp (RGD)

et al. 2012

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…None of these clinical trials or subgroup analyses focused on the elderly but exploratory subgroup analyses were published showing no influence of older age in efficacy of ramucirumab in both phase III RAINBOW and REGARD clinical trials [100]. Few retrospective studies are available, showing a similar benefit for second-line therapies in older versus younger patients [101][102][103]. Age above 60 years was recently identified as an independent good prognostic factor for PFS and OS in a post-hoc analysis of the phase III FFCD-0307 trial, but probably due a selection bias [104].…”

Section: Hematologic Risk Factorsmentioning

confidence: 99%

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature

Fouchardiere

Decoster

Samalin

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

Gastric (G) and gastro-esophageal junction (GEJ) adenocarcinomas are of the most common and deadly cancers worldwide and affect mainly patients over 70 years at diagnosis. Older age has been associated in gastric cancers with distal tumour location, well-differentiated adenocarcinoma and microsatellite instability and is not identified itself as an independent prognostic factor. As immune checkpoint inhibitors recently changed the landmark of advanced G and GEJ adenocarcinomas treatment, we decided to perform a literature review to define the evidence-level of clinical data in older patients. This work underlined the lasting low -inclusion rate of older patients and -implementation rate of frailty screening tools in clinical trials in G/GEJ carcinomas. In the first-line metastatic setting, two prospective randomized phase III studies have specifically assessed the efficacy of chemotherapy in older patients with HER2-negative gastric cancers, demonstrating the feasibility of reduced dose oxaliplatin-based chemotherapy regimen in this population. Only few data are available in HER2-positive tumors, or in the second-line setting. Furthermore, no specific trial with immune checkpoint inhibitors was performed in older frail patients whereas their benefit/adverse events ratio make them attractive candidates in this patient's population. We conclude that older fit patients can be treated in the same way as younger ones and included in clinical trials. Improving the outcome of older frail patients should be the oncology community next focus by implementing targeted interventions before initiating cancer therapy and designing specific clinical trials. Frailty screening tools and geriatric data collection have to be implemented in routine-practice and clinical trials.

show abstract

Massive Diffuse Alveolar Hemorrhage Caused by the Aspiration of Gastric Contents during Induction of Anesthesia in Patients with Adhesive Ileus - A Case Report -

Jeong

Jun

Song

et al. 2012

Korean J Crit Care Med

View full text Add to dashboard Cite

Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer

Cited by 3 publications

References 20 publications

Targeted Delivery of Insoluble Cargo (Paclitaxel) by PEGylated Chitosan Nanoparticles Grafted with Arg-Gly-Asp (RGD)

Targeted Delivery of Insoluble Cargo (Paclitaxel) by PEGylated Chitosan Nanoparticles Grafted with Arg-Gly-Asp (RGD)

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature

Massive Diffuse Alveolar Hemorrhage Caused by the Aspiration of Gastric Contents during Induction of Anesthesia in Patients with Adhesive Ileus - A Case Report -

Contact Info

Product

Resources

About